
Walter Mier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4263685/publications.pdf Version: 2024-02-01



WAITED MIED

#	Article	IF	CITATIONS
1	Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics. Pharmaceuticals, 2022, 15, 159.	1.7	2
2	[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3011-3013.	3.3	60
3	Virus-Derived Peptides for Hepatic Enzyme Delivery. Molecular Pharmaceutics, 2021, 18, 2004-2014.	2.3	1
4	Mass Spectrometric Quantification of the Antimicrobial Peptide Pep19-2.5 with Stable Isotope Labeling and Acidic Hydrolysis. Pharmaceutics, 2021, 13, 1342.	2.0	0
5	Trends in liposomal nanocarrier strategies for the oral delivery of biologics. Nanomedicine, 2021, 16, 1813-1832.	1.7	7
6	18F-labeled tracers targeting fibroblast activation protein. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 26.	1.8	38
7	Overcoming the Mucosal Barrier: Tetraether Lipid‣tabilized Liposomal Nanocarriers Decorated with Cellâ€Penetrating Peptides Enable Oral Delivery of Vancomycin. Advanced Therapeutics, 2021, 4, 2000247.	1.6	16
8	Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Journal of Nuclear Medicine, 2020, 61, 70-79.	2.8	23
9	Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria. Canadian Journal of Microbiology, 2020, 66, 11-16.	0.8	75
10	Response Prediction of ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. Journal of Nuclear Medicine, 2020, 61, 689-695.	2.8	39
11	Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102132.	1.7	38
12	Innenrücktitelbild: Überwindung von Vancomycinresistenzen durch Modifikation mit polykationischen Peptiden (Angew. Chem. 23/2020). Angewandte Chemie, 2020, 132, 9277-9277.	1.6	0
13	Fatty Acid Conjugation Leads to Length-Dependent Antimicrobial Activity of a Synthetic Antibacterial Peptide (Pep19-4LF). Antibiotics, 2020, 9, 844.	1.5	12
14	Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci. Pharmaceuticals, 2020, 13, 110.	1.7	15
15	Vancomycin Resistance Is Overcome by Conjugation of Polycationic Peptides. Angewandte Chemie - International Edition, 2020, 59, 8823-8827.	7.2	56
16	Überwindung von Vancomycinresistenzen durch Modifikation mit polykationischen Peptiden. Angewandte Chemie, 2020, 132, 8908-8912.	1.6	0
17	Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery. Journal of Controlled Release, 2020, 322, 200-208.	4.8	30
18	Design and Development of ^{99m} Tc-Labeled FAPI Tracers for SPECT Imaging and ¹⁸⁸ Re Therapy. Journal of Nuclear Medicine, 2020, 61, 1507-1513.	2.8	110

#	Article	IF	CITATIONS
19	⁶⁸ Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. Journal of Nuclear Medicine, 2019, 60, 386-392.	2.8	468
20	Targeting prostate cancer: Prostateâ€specific membrane antigen based diagnosis and therapy. Medicinal Research Reviews, 2019, 39, 40-69.	5.0	88
21	Replacement of l-Amino Acids by d-Amino Acids in the Antimicrobial Peptide Ranalexin and Its Consequences for Antimicrobial Activity and Biodistribution. Molecules, 2019, 24, 2987.	1.7	18
22	DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. Mutagenesis, 2019, 34, 239-244.	1.0	12
23	Preclinical evaluation of peptide-based radiotracers for integrin αvβ6-positive pancreatic carcinoma. Nuklearmedizin - NuclearMedicine, 2019, 58, 309-318.	0.3	8
24	Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention. Journal of Nuclear Medicine, 2019, 60, 1421-1429.	2.8	281
25	⁶⁸ Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. Journal of Nuclear Medicine, 2019, 60, 801-805.	2.8	874
26	PET/CT Imaging of NSCLC with a αvβ6 Integrin-Targeting Peptide. Molecular Imaging and Biology, 2019, 21, 973-983.	1.3	21
27	Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model. Oncolmmunology, 2019, 8, e1524694.	2.1	8
28	Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 82-93.	1.7	40
29	Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead―into PSMA-targeted alpha therapy?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1081-1091.	3.3	77
30	Dosimetry Estimate and Initial Clinical Experience with ⁹⁰ Y-PSMA-617. Journal of Nuclear Medicine, 2019, 60, 806-811.	2.8	27
31	Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide. ELife, 2019, 8, .	2.8	20
32	Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1179-1187.	3.3	26
33	Comparison of the RGD Motif–Containing α _v β ₆ Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. Journal of Nuclear Medicine, 2018, 59, 1679-1685.	2.8	38
34	A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. Journal of Nuclear Medicine, 2018, 59, 1423-1429.	2.8	453
35	Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. Journal of Nuclear Medicine, 2018, 59, 1415-1422.	2.8	522
36	A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. International Journal of Antimicrobial Agents, 2018, 52, 52-62.	1.1	24

#	Article	IF	CITATIONS
37	Intraindividual Comparison of ^{99m} Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^{99m} Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1373-1379.	2.8	31
38	Repeated ¹⁷⁷ Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. Journal of Nuclear Medicine, 2018, 59, 459-465.	2.8	68
39	Characterization of a Threonine-Rich Cluster in Hepatitis C Virus Nonstructural Protein 5A and Its Contribution to Hyperphosphorylation. Journal of Virology, 2018, 92, .	1.5	7
40	Phenomenon of Endothelial Antibody Capture: Principles and Potential for Locoregional Targeting of Hepatic Tumors. Hepatology, 2018, 68, 1804-1816.	3.6	9
41	Strategies for the treatment of HBV/HDV. European Journal of Pharmacology, 2018, 833, 379-391.	1.7	16
42	Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy. Oncotarget, 2018, 9, 29985-30004.	0.8	11
43	The Clinical Impact of Additional Late PET/CT Imaging with ⁶⁸ Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 750-755.	2.8	105
44	Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 950-959.	3.3	69
45	⁶⁸ Ga or ¹⁸ F for Prostate Cancer Imaging?. Journal of Nuclear Medicine, 2017, 58, 687-688.	2.8	105
46	Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1258-1268.	3.3	425
47	Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display. Clinical Cancer Research, 2017, 23, 4170-4180.	3.2	37
48	⁶⁸ Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. Journal of Nuclear Medicine, 2017, 58, 1943-1948.	2.8	81
49	A scavenger peptide prevents methylglyoxal induced pain in mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 654-662.	1.8	30
50	A Polymer/Peptide Complexâ€Based Sensor Array That Discriminates Bacteria in Urine. Angewandte Chemie - International Edition, 2017, 56, 15246-15251.	7.2	130
51	A Polymer/Peptide Complexâ€Based Sensor Array That Discriminates Bacteria in Urine. Angewandte Chemie, 2017, 129, 15448-15453.	1.6	15
52	Identification of Ligands and Translation to Clinical Applications. Journal of Nuclear Medicine, 2017, 58, 27S-33S.	2.8	16
53	Oral delivery of vancomycin by tetraether lipid liposomes. European Journal of Pharmaceutical Sciences, 2017, 108, 111-118.	1.9	69
54	Improving the Imaging Contrast of ⁶⁸ Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjugate Chemistry, 2017, 28, 2485-2492.	1.8	40

#	Article	IF	CITATIONS
55	⁶⁸ Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1949-1955.	2.8	27
56	Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients. Cancer Imaging, 2017, 17, 30.	1.2	8
57	Multicyclic Peptides as Scaffolds for the Development of Tumor Targeting Agents. Current Medicinal Chemistry, 2017, 24, 2141-2155.	1.2	11
58	Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals. Theranostics, 2016, 6, 1085-1095.	4.6	60
59	A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 103, 159-166.	2.0	63
60	Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes. International Journal of Pharmaceutics, 2016, 512, 87-95.	2.6	33
61	Preclinical evaluation of a diabody-based 177Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. Cancer Letters, 2016, 381, 296-304.	3.2	3
62	Drug Conjugation Affects Pharmacokinetics and Specificity of Kidney-Targeted Peptide Carriers. Bioconjugate Chemistry, 2016, 27, 2441-2449.	1.8	21
63	A Slow Maturation Process Renders Hepatitis B Virus Infectious. Cell Host and Microbe, 2016, 20, 25-35.	5.1	50
64	Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. Journal of Translational Medicine, 2016, 14, 99.	1.8	8
65	18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1929-1930.	3.3	81
66	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷ Lu-Labeled PSMA-617. Journal of Nuclear Medicine, 2016, 57, 1170-1176.	2.8	475
67	Renal Targeting: Peptide-Based Drug Delivery to Proximal Tubule Cells. Bioconjugate Chemistry, 2016, 27, 1050-1057.	1.8	62
68	Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 1761-1775.	2.9	150
69	Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Gastroenterology, 2016, 150, 513-525.e10.	0.6	78
70	High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 489-498.	3.3	13
71	Advantages in functional imaging of the brain. Frontiers in Human Neuroscience, 2015, 9, 249.	1.0	61
72	A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells. Journal of Immunology Research, 2015, 2015, 1-14.	0.9	19

#	Article	IF	CITATIONS
73	Impaired uptake of conjugated bile acids and hepatitis b virus pres1â€binding in na+â€ŧaurocholate cotransporting polypeptide knockout mice. Hepatology, 2015, 62, 207-219.	3.6	116
74	An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo. Cancer Letters, 2015, 357, 364-373.	3.2	9
75	Cancer Stratification by Molecular Imaging. International Journal of Molecular Sciences, 2015, 16, 4918-4946.	1.8	20
76	Generation of suppressive blood cells for control of allograft rejection. Clinical Science, 2015, 128, 593-607.	1.8	19
77	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 914-920.	2.8	451
78	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Journal of Nuclear Medicine, 2015, 56, 1697-1705.	2.8	332
79	Radionuclides in drug development. Drug Discovery Today, 2015, 20, 198-208.	3.2	29
80	Therapeutical Administration of Peptide Pep19-2.5 and Ibuprofen Reduces Inflammation and Prevents Lethal Sepsis. PLoS ONE, 2015, 10, e0133291.	1.1	9
81	Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs. Molecules, 2014, 19, 2135-2165.	1.7	48
82	Current Status in the Therapy of Liver Diseases. International Journal of Molecular Sciences, 2014, 15, 7500-7512.	1.8	34
83	Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide ¹³¹ I-BA52. Journal of Nuclear Medicine, 2014, 55, 9-14.	2.8	48
84	Essential role of sympathetic endothelin A receptors for adverse cardiac remodeling. Proceedings of the United States of America, 2014, 111, 13499-13504.	3.3	30
85	Is nano too big?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 4-6.	3.3	14
86	Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1280-1292.	3.3	319
87	Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics. Clinical and Translational Imaging, 2014, 2, 33-41.	1.1	1
88	Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. Journal of Hepatology, 2014, 60, 723-731.	1.8	217
89	Selective targeting of liver cancer with the endothelial marker CD146. Oncotarget, 2014, 5, 8614-8624.	0.8	15
90	Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics. Current Pharmaceutical Biotechnology, 2014, 15, 200-209.	0.9	11

#	Article	IF	CITATIONS
91	Pharmacokinetic Properties of Peptidic Radiopharmaceuticals: Reduced Uptake of (EH) ₃ -Conjugates in Important Organs. Journal of Nuclear Medicine, 2013, 54, 1327-1330.	2.8	24
92	A Disulfide onstrained Miniprotein with Striking Tumorâ€Binding Specificity Developed by Ribosome Display. Angewandte Chemie - International Edition, 2013, 52, 11760-11764.	7.2	11
93	Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology, 2013, 58, 31-42.	3.6	113
94	PEGylation enables the specific tumor accumulation of a peptide identified by phage display. Organic and Biomolecular Chemistry, 2013, 11, 2706.	1.5	8
95	A Mild Method for Regioselective Labeling of Aromatics with Radioactive Iodine. European Journal of Organic Chemistry, 2013, 2013, 3970-3973.	1.2	10
96	Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology, 2013, 58, 43-53.	3.6	102
97	Liver Imaging with a Novel Hepatitis B Surface Protein Derived SPECT-Tracer. Molecular Pharmaceutics, 2013, 10, 2230-2236.	2.3	6
98	Screening of a Novel Peptide Targeting the Proteoglycan-Like Region of Human Carbonic Anhydrase IX. Molecular Imaging, 2013, 12, 7290.2013.00066.	0.7	17
99	Synthesis of Peptide Radiopharmaceuticals for the Therapy and Diagnosis of Tumor Diseases. Molecules, 2013, 18, 3379-3409.	1.7	74
100	DOTA-Functionalized Polylysine: A High Number of DOTA Chelates Positively Influences the Biodistribution of Enzymatic Conjugated Anti-Tumor Antibody chCE7agl. PLoS ONE, 2013, 8, e60350.	1.1	28
101	Acid-Mediated Prevention of Aspartimide Formation in Solid Phase Peptide Synthesis. Organic Letters, 2012, 14, 5218-5221.	2.4	55
102	DOTA-tris(OPp ester) as a bifunctional prochelator for the preparation of DOTA–peptide conjugates. Tetrahedron Letters, 2012, 53, 6810-6814.	0.7	7
103	Combination of Phage Display and Molecular Grafting Generates Highly Specific Tumorâ€Targeting Miniproteins. Angewandte Chemie - International Edition, 2012, 51, 13136-13139.	7.2	34
104	A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Research, 2012, 2, 23.	1.1	134
105	⁶⁸ Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjugate Chemistry, 2012, 23, 688-697.	1.8	709
106	Engineering and Functionalization of the Disulfideâ€Constrained Miniprotein Minâ€⊋3 as a Scaffold for Diagnostic Application. ChemMedChem, 2012, 7, 237-247.	1.6	14
107	DNA Libraries for the Construction of Phage Libraries: Statistical and Structural Requirements and Synthetic Methods. Molecules, 2011, 16, 1625-1641.	1.7	22
108	Miniproteins as Phage Display-Scaffolds for Clinical Applications. Molecules, 2011, 16, 2467-2485.	1.7	31

#	Article	IF	CITATIONS
109	Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocrine-Related Cancer, 2011, 18, 595-602.	1.6	79
110	68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1397-1407.	3.3	50
111	Hot or not—the influence of elevated temperature and microwave irradiation on the solid phase synthesis of an affibody. Tetrahedron Letters, 2010, 51, 6216-6219.	0.7	12
112	Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction. Journal of Virology, 2010, 84, 1989-2000.	1.5	201
113	Endoradiotherapy in cancer treatment — Basic concepts and future trends. European Journal of Pharmacology, 2009, 625, 55-62.	1.7	46
114	Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1878-1886.	3.3	93
115	PAMAM Structureâ€Based Multifunctional Fluorescent Conjugates for Improved Fluorescent Labelling of Biomacromolecules. Chemistry - A European Journal, 2008, 14, 8116-8130.	1.7	35
116	Improved syntheses and applicability of different DOTA building blocks for multiply derivatized scaffolds. Bioorganic and Medicinal Chemistry, 2008, 16, 2606-2616.	1.4	41
117	Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotechnology, 2008, 26, 335-341.	9.4	369
118	Endoradiotherapy with Peptides - Status and Future Development. Current Medicinal Chemistry, 2008, 15, 219-234.	1.2	28
119	Radiolabeled Peptides and Proteins in Cancer Therapy. Protein and Peptide Letters, 2007, 14, 273-279.	0.4	25
120	Identification and Evaluation of a New Tumor Cell-Binding Peptide, FROP-1. Journal of Nuclear Medicine, 2007, 48, 965-972.	2.8	30
121	Influence of Chelate Conjugation on a Newly Identified Tumor-Targeting Peptide. Journal of Nuclear Medicine, 2007, 48, 1545-1552.	2.8	17
122	Manual Solid–Phase Peptide Synthesis of Metallocene–Peptide Bioconjugates. Journal of Chemical Education, 2007, 84, 108.	1.1	60
123	Synthesis and evaluation of intercalating somatostatin receptor binding peptide conjugates for endoradiotherapy. Journal of Pharmacy and Pharmaceutical Sciences, 2007, 10, 286s-297s.	0.9	4
124	Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. Journal of Nuclear Medicine, 2006, 47, 981-8.	2.8	27
125	Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, p160. Clinical Cancer Research, 2005, 11, 6705-6712.	3.2	71
126	Conjugation of DOTA Using Isolated Phenolic Active Esters:  The Labeling and Biodistribution of Albumin as Blood Pool Marker. Bioconjugate Chemistry, 2005, 16, 237-240.	1.8	57

#	Article	IF	CITATIONS
127	A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clinical Cancer Research, 2005, 11, 139-46.	3.2	61
128	Identification of a new prostate-specific cyclic peptide with the bacterial FliTrx system. Journal of Nuclear Medicine, 2005, 46, 782-5.	2.8	24
129	Synthesis of peptide conjugated chelator oligomers for endoradiotherapy and MRT imaging. Tetrahedron Letters, 2004, 45, 5453-5455.	0.7	14
130	Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Nuclear Medicine and Biology, 2004, 31, 21-30.	0.3	19
131	Fluorescent Somatostatin Receptor Probes for the Intraoperative Detection of Tumor Tissue with Long-Wavelength Visible Light. Bioorganic and Medicinal Chemistry, 2002, 10, 2543-2552.	1.4	17
132	A general method for functionalising both the C- and N-terminals of Tyr 3 -octreotate. Tetrahedron Letters, 2002, 43, 5021-5024.	0.7	17
133	DNA adduct formation by the ubiquitous environmental contaminant 3-nitrobenzanthrone in rats determined by32P-postlabeling. International Journal of Cancer, 2001, 93, 450-454.	2.3	75